FDA expands Novartis remibrutinib approval for symptomatic dermographism
The FDA approved remibrutinib to treat adults with symptomatic dermographism inadequately controlled with H1 antihistamines, expanding the drug's indication beyond its initial approval.
2 sourcesFDA drug approval
00